[{"orgOrder":0,"company":"IMV","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Maveropepimut-S","moa":"T cell","graph1":"Oncology","graph2":"Phase II","graph3":"IMV","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"IMV \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IMV \/ Not Applicable"},{"orgOrder":0,"company":"IMV","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Maveropepimut-S","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"IMV","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"IMV \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IMV \/ Not Applicable"},{"orgOrder":0,"company":"IMV","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Maveropepimut-S","moa":"T cell","graph1":"Oncology","graph2":"Phase II","graph3":"IMV","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"IMV \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IMV \/ Not Applicable"},{"orgOrder":0,"company":"IMV","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2022","type":"Public Offering","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"IMV","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"IMV \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"IMV \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"IMV","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2022","type":"Public Offering","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"IMV","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"IMV \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"IMV \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"IMV","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Maveropepimut-s","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"IMV","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"IMV \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IMV \/ Not Applicable"},{"orgOrder":0,"company":"IMV","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"Maveropepimut-s","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"IMV","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"IMV \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IMV \/ Not Applicable"},{"orgOrder":0,"company":"IMV","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"IMV","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"IMV \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IMV \/ Not Applicable"},{"orgOrder":0,"company":"Immunovaccine Technologies","sponsor":"Biovaxys","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2024","type":"Acquisition","leadProduct":"Maveropepimut-S","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Immunovaccine Technologies","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"Immunovaccine Technologies \/ BioVaxys","highestDevelopmentStatusID":"8","companyTruncated":"Immunovaccine Technologies \/ BioVaxys"}]

Find Clinical Drug Pipeline Developments & Deals for Maveropepimut-S

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Immunovaccine Technologies

                          Country arrow
                          CPhI India 2024
                          Not Confirmed

                          Immunovaccine Technologies

                          Country arrow
                          CPhI India 2024
                          Not Confirmed

                          Details : The acquisition supplements BioVaxys' cancer vaccine portfolio with DPX-Survivac, a cancer vaccine delivering antigenic peptides from survivin, commonly overexpressed in advanced cancers.

                          Brand Name : DPX-Survivac

                          Molecule Type : Vaccine

                          Upfront Cash : $25.7 million

                          February 12, 2024

                          Lead Product(s) : Maveropepimut-S,Pembrolizumab,Cyclophosphamide

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Biovaxys

                          Deal Size : $25.7 million

                          Deal Type : Acquisition

                          blank

                          02

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : IMV’s lead candidate, DPX-Survivac (maveropepimut-S), delivers antigenic peptides from survivin, a well-recognized cancer antigen commonly overexpressed in advanced cancers.

                          Brand Name : DPX-Survivac

                          Molecule Type : Vaccine

                          Upfront Cash : Not Applicable

                          February 13, 2023

                          Lead Product(s) : Maveropepimut-S,Pembrolizumab,Cyclophosphamide

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : IMV’s lead candidate, DPX-Survivac (maveropepimut-S), delivers antigenic peptides from survivin, a well-recognized cancer antigen commonly overexpressed in advanced cancers.

                          Brand Name : DPX-Survivac

                          Molecule Type : Vaccine

                          Upfront Cash : Not Applicable

                          January 08, 2023

                          Lead Product(s) : Maveropepimut-S,Pembrolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : DPX-Survivac (maveropepimut-S) is a novel T cell immunotherapy that uses the DPX platform to elicit strong and sustained survivin-specific T cell responses against tumor cells.

                          Brand Name : DPX-Survivac

                          Molecule Type : Vaccine

                          Upfront Cash : Undisclosed

                          December 20, 2022

                          Lead Product(s) : Maveropepimut-S,Pembrolizumab,Cyclophosphamide

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : H.C. Wainwright & Co.

                          Deal Size : $9.0 million

                          Deal Type : Public Offering

                          blank

                          05

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : DPX-Survivac (maveropepimut-S) is a novel T cell immunotherapy that uses the DPX platform to elicit strong and sustained survivin-specific T cell responses against tumor cells.

                          Brand Name : DPX-Survivac

                          Molecule Type : Vaccine

                          Upfront Cash : Undisclosed

                          December 16, 2022

                          Lead Product(s) : Maveropepimut-S,Pembrolizumab,Cyclophosphamide

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : H.C. Wainwright & Co.

                          Deal Size : $9.0 million

                          Deal Type : Public Offering

                          blank

                          06

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : IMV’s lead candidate, DPX-Survivac (maveropepimut-S, MVP-S), delivers antigenic peptides from survivin, a well-recognized cancer antigen commonly overexpressed in advanced cancers.

                          Brand Name : DPX-Survivac

                          Molecule Type : Vaccine

                          Upfront Cash : Not Applicable

                          December 15, 2022

                          Lead Product(s) : Maveropepimut-S,Pembrolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : Maveropepimut-S (DPX-Survivac) Generating Cancer-Targeted Killer T Cells combines advantages of DPX platform and cancer antigen survivin, is lead candidate of IMV’s new class of immunotherapies that generates cancer-targeted T cells in vivo.

                          Brand Name : DPX-Survivac

                          Molecule Type : Vaccine

                          Upfront Cash : Not Applicable

                          April 28, 2022

                          Lead Product(s) : Maveropepimut-S,Cyclophosphamide

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : Combination of DPX-Survivac (maveropepimut-s) and pembrolizumab showed encouraging clinical activity in advanced, metastatic bladder cancer patients, particularly in patients who had received prior immune checkpoint inhibitor therapy.

                          Brand Name : DPX-Survivac

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          April 08, 2022

                          Lead Product(s) : Maveropepimut-S,Pembrolizumab,Cyclophosphamide

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          09

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : DPX-Survivac, a novel T cell immunotherapy that uses the DPX platform to elicit a coordinated anti-tumor immune response involving natural killer cells in both translational and preclinical studies.

                          Brand Name : DPX-Survivac

                          Molecule Type : Vaccine

                          Upfront Cash : Not Applicable

                          March 09, 2022

                          Lead Product(s) : Maveropepimut-S,Cyclophosphamide

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank